Core Insights - Klotho Neuroscience, Inc. is partnering with leading researchers from the Okinawa Research Center for Longevity Science to explore the role of the Klotho gene in promoting longevity and reducing neurodegenerative diseases [1][2][3] Company Overview - Klotho Neuroscience, Inc. (NASDAQ: KLTO) focuses on developing cell and gene therapies targeting neurological conditions such as ALS, Alzheimer's Disease, and Parkinson's Disease [1][4] - The company utilizes a patented form of the Klotho gene, specifically the secreted alpha-Klotho protein isoform (s-KL), in its innovative therapies [4] Research and Development - Preliminary data from ORCLS suggests that the alpha-Klotho gene and its protein isoform may contribute to healthy longevity, with decreased levels correlating with various age-related diseases [2][3] - The partnership will analyze blood samples from centenarians to assess the Klotho protein's role in longevity and its potential protective effects against neurodegenerative disorders [3][4] Historical Context - Okinawa is recognized as the original Blue Zone, known for its high concentration of centenarians, validated by extensive research from ORCLS over the past five decades [2][3] - ORCLS has a history of significant discoveries in human aging, including the identification of longevity genes and their translation from model organisms to humans [3]

Core Insights - Klotho Neurosciences, Inc. has terminated its Share Exchange Agreement with SkyBell Technologies, allowing the company to focus on its core R&D programs and enhance shareholder value [2][3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company specializing in innovative, disease-modifying cell and gene therapies derived from the anti-aging human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [4] Strategic Implications - The termination of the agreement eliminates the need to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of Klotho, thereby preventing significant dilution of existing shareholders [7] - The company will not incur any liability as a result of this termination, allowing it to refocus its strategy and allocate resources towards advancing its primary therapeutic and longevity programs [7]

Group 1 - Klotho Neurosciences, Inc. raised over $11 million through the exercise of existing warrants by investors [1][6] - The company believes it now exceeds Nasdaq's stockholders' equity requirements outlined in its compliance plan [1][6] - Klotho utilized $3.1 million of the raised funds to extinguish all outstanding debt, resulting in a debt-free balance sheet [2][6] Group 2 - Klotho Neurosciences focuses on developing innovative, disease-modifying cell and gene therapies targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [3] - The company's portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays [3] - Klotho is managed by a team experienced in biopharmaceutical product development and commercialization [3]